https://www.gsk.com/en-gb/media/press-releases/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases.
us fdaexpandsjemperlidostarlimabplus